Telephone 020 3813 2890 for a free no obligation chat about your regulatory requirements with one of our compliance consultants.
© Compound Growth Limited 2012 - 2018 | Terms of Use
Registered in England and Wales as limited company number 07626537 - Registered Office 120 Pall Mall, London, SW1Y 5EA
We use cookies, if you consent to this use, please continue to browse our site.
Here to help with Regulation and Compliance
ISPVs Authorisation & Supervision by the Regulators
24th November 2016
The Regulators on Insurance Special Purpose Vehicles (ISPVs)
The FCA and PRA have entered into a joint consultation (FCA CP16/34 or PRA CP42/16) in relation to the regulatory authorisation and supervision of Insurance Special Purpose Vehicles (ISPVs) - with particular regards to Insurance Linked Securities (ILS) business.
At present, HM Treasury has entered a second consultation on regulations that will introduce a new regulatory and tax framework for Insurance Linked Securities (ILS) business. The first consultation upon this subject sought initial views on the regulatory, tax and corporate structure framework for ILS business whilst the second consultation looks to sets out additional details on the proposed new approach and implementation. This new framework is time-tabled to take effect sometime in the Spring of next year (2017).
Included within the new framework is the proposal that includes a new corporate structure – the Protected Cell Company (PCC). The structure of a PCC is ‘intended to allow each contract for risk transfer to be established as a separate cell.’
Once the new regulatory framework has been implemented, the UK regulators (FCA and PRA) will then expect to be able to accept applications for authorisation of ISPVs.
Insurance Risk Transformation will be a new regulatory activity that is introduced and for which ISPVs will need to apply. Additionally, the PRA is also consulting upon new authorisation forms for this purpose.
Since ISPVs are entities that are regulated by both the UK regulators (i.e. dual-regulated firms), they will still need to apply to the PRA for their authorisation for this activity. The FCA will then need to give consent for approval of the authorisation.
The regulators are encouraging applicants for this new regulatory activity to ‘engage with the regulators prior to submitting’ their applications, particularly given the time-sensitive nature of Insurance Linked Securities transactions.
Assuming that a firm engages with the regulators prior to application and the entity’s proposal is relatively straight-forward (and accompanied by good quality supporting documentation), the regulators anticipate that applications should be determined within 6-8 weeks.
Once the new protected cell company (PCC) corporate structure has been established, it is the Financial Conduct Authority (FCA) rather than Companies House that intends to be responsible for a PCC’s registration and incorporation.
The consultation proposes that prior to an ISPV establishing any new cells, the PRA would require the ISPV to notify them and submit a pre-transaction notification form, which would also be reviewed by the FCA.
The joint consultation will continue until the 23rd February 2017, which is the deadline for receiving comments on the regulators proposals. Following the consultation, the regulators will look to see how best to incorporate the new ILS framework into the FCA’s regulatory Handbook at the start of next year.
Read our latest articles, news and views affecting compliance and regulation in the UK Financial Services Industry.
Comment from the FCA
“The ILS market may continue to develop as experience of operating in the UK regulated environment grows. The regulators will keep their rules and guidance under review and assess whether any amendments to the regulatory approach may be needed as the market matures.”
FCA CP16/34 November 2016
Please contact our Compliance Support Team for a free no obligation discussion of your regulatory requirements and how our regulatory & compliance consultants can help your business move forward compliantly.
Call by Telephone:
(020) 3813 2890